# Analyst A — pathway options review and reconciliation

27 October 2026 (America/Chicago); Analyst B's handoff is dated 28 October 2026 UTC.
Base: `3b32c257fbc8e5d8949444bb8439d74562ed46b2`.
Analyst A = Codex; Analyst B = Claude.ai. Reviewed B's shared handoff and patch; no internal agent was substituted for B.

## Accepted design

- The default pathway view presents all protocol result options without finding selectors.
- Each decision retains its three columns and pinned decision navigation.
- The middle column presents what is assessed, definitions, possible results, relevant high-risk reviews, visible reassessment reasons and outcome evidence.
- Results retain the protocol's titles, actions, criteria and source identities. Compact Applies when and Evidence & sources controls open inline.
- The original finding-by-finding workflow remains an optional Tools action. Its per-pathway display preference is saved; clinical findings remain in the current tab.
- High-risk reviews remain orange, with the original scope, proposed/closed status and reference link visible.
- Opening a treatment or high-risk reference from a static option does not claim that a patient has met its criteria.

## Analyst A corrections

1. **Yao cohort label.** Changed “Downstaged vs within-T2 at listing” to “Downstaging cohort vs T2 at listing”. The former could suggest that all entrants were successfully downstaged. Cohort sizes, survival estimates and limitations were checked against the [primary report](https://pmc.ncbi.nlm.nih.gov/articles/PMC4809192/) and the V15 source quotes. Different intention-to-treat time origins and treatment-related decompensation remain explicit.
2. **Phone mode switch.** Choosing the optional step-by-step mode now opens Results & criteria automatically. The original patch changed modes while leaving the phone on Tools, with the requested controls hidden.
3. **Storage wording.** Replaced “nothing is saved” with a precise statement that findings stay in the tab and are not saved. The viewing preference is intentionally persistent.
4. **Standing hierarchy.** Updated the general hierarchy rule to reflect the user's new default: possible results with explicit high-risk triggers, alongside the optional matched-result view.

The first corrected Yao label exceeded the compact-evidence length guard. It was shortened without removing the cohort distinction, then the evidence build and its validator passed. No baseline or threshold was relaxed.

## Independent checks

- 17 Node suites passed.
- Six Python suites passed after the compact label correction; 485 study summaries are source-traced.
- 1,339 deck-sourced quotes verified in 15 V15 decks.
- 29/29 protected clinical-source hashes unchanged.
- All 46 pathway decisions checked on desktop and at 390 × 844: 89 protocol branch options, 205 source-row placements and 35 high-risk review placements. Titles, actions, types, criteria, source counts, reassessment statements and high-risk contexts match the embedded protocol data.
- Every criteria/evidence peer was opened on all 46 phone decision views; no page-level horizontal overflow.
- Next-step links and optional finding selection exercised on all seven pathways.
- Phone mode transitions open the correct tab in both directions; source dialogs open and close.
- Static HCC treatment links open as treatment references without recorded-patient context. AFP high-risk review opens with orange heading and reference status.
- All 103 topics across 12 roadmaps checked; no missing study result rows or pathway-only styling. Systemic matrix retains 49 cards.
- No browser warnings or errors in the preview session.

Detailed JSON reports, initial test logs and screenshots are retained in this folder. B's browser test is retained in the repository; A performed its independent UI checks through the Codex browser interface. This is a presentation and content-preservation review, not institutional clinical approval.
